Scarica l'app Stockscreener
4.57
0.33%
0.04
Precedente Chiudi:
$4.53
Aprire:
$4.55
Volume 24 ore:
108.66K
Relative Volume:
0.25
Capitalizzazione di mercato:
$364.52M
Reddito:
$351.37M
Utile/perdita netta:
$-158.35M
Rapporto P/E:
-2.3408
EPS:
-1.9523
Flusso di cassa netto:
$-132.03M
1 W Prestazione:
+8.47%
1M Prestazione:
-15.21%
6M Prestazione:
+49.02%
1 anno Prestazione:
+54.07%
Intervallo 1D:
$4.47
$4.66
Intervallo di 1 settimana:
$4.20
$4.66
Portata 52W:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 284-8891
Indirizzo
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.555 | 362.52M | 351.37M | -158.35M | -132.03M | -1.9523 |
VRTX
Vertex Pharmaceuticals Inc
|
441.12 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.54 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
823.07 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.44 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.97 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Atea presents hepatitis C drug interaction data at EASL - Investing.com
No hepatitis E drugs: Atea antiviral 30–150x more potent in lab - Stock Titan
Atea Pharmaceuticals (AVIR) Gains 4.25% as Biotech Sentiment Lifts the StockValue Factor - Newser
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks - Yahoo Finance
Atea Pharmaceuticals (AVIR) Edges Higher Amid Renewed Investor InterestBuffered ETF - Newser
Atea Pharmaceuticals (AVIR) Gains 4.25% as Stock Tests Key Resistance LevelOn Balance Volume - Newser
Atea Pharmaceuticals (AVIR) Shows Modest Uptick, Holding Above Key SupportCommunity Pattern Alerts - Newser
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock By Investing.com - Investing.com Canada
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock - Investing.com
Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock - Stock Titan
Atea Pharmaceuticals Q1 earnings call highlights - MSN
Atea (AVIR) director adds 6,100 shares in open-market purchase - Stock Titan
Atea Pharma (AVIR) Stock: Up +1.69%, Key Resistance at $4.42 2026-05-19Community Exit Signals - Newser
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss - Investing.com Nigeria
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $4.1 - Moomoo
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - Sahm
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully - Sahm
Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call - TipRanks
Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2026 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026 - Quiver Quantitative
Atea Pharmaceuticals to Present Three Abstracts at EASL - GlobeNewswire
Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027 - MSN
Atea Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-05-12 - Seeking Alpha
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reports slight EPS miss, stock dips - Investing.com Nigeria
Atea Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results - TradingView
Atea Pharmaceuticals reports Q1 2026 net loss $45.4M, cash & marketable securities $256.0M - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom - ChartMill
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AVIR: HCV and HEV programs advance toward key milestones as R&D spending drives higher net loss - TradingView
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Atea (NASDAQ: AVIR) advances HCV, HEV pipeline as Q1 loss widens - Stock Titan
Atea Pharmaceuticals : Q1 26 IR Slide Deck 5 12 26 FINAL - marketscreener.com
Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
TradingKey - TradingKey
Atea Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Corcoran Andrea - Moomoo
[SCHEDULE 13G/A] Atea Pharmaceuticals, Inc. Amended Passive Investment Disclosure - Stock Titan
Atea sets May 12 webcast for quarterly results and business update - Stock Titan
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 - The Manila Times
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update ... - Caledonian Record
Atea Pharmaceuticals (AVIR) price target increased by 25.00% to 10.20 - MSN
AVIR | Atea Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atea Pharmaceuticals Inc Azioni (AVIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
| Murphy Polly A. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
86,045 |
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
0.67%
1.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):